000504 Landfar Bio-medicine
- 7.25
- -0.20-2.68%
Landfar Bio-medicine News
The concept of cellular immunotherapy fluctuated and declined. Jimin Medical and Nanhua Biotech fell to a standstill, Tailin Biotech fell by more than 8%, and Nanjing Xinbai and Sihuan Biotech followed suit.
The concept of cellular immunotherapy fluctuated and declined. Jimin Medical and Nanhua Biotech fell to a standstill, Tailin Biotech fell by more than 8%, and Nanjing Xinbai and Sihuan Biotech followed suit.
The A-share cell immunotherapy concept continued to decline, and Xuerong Biotech declined by more than 10%
Gelonghui, May 13 | Xuerong Biotech fell more than 10%. Nanhua Biotech and Jimin Medical had previously fallen to a standstill, while Guanhao Biotech and Kaineng Health had the highest declines.
Express News | Nanhua Biotech: There are currently no important matters that should be disclosed but not disclosed
Nanhua Biology (000504.SZ): The company does not yet have synthetic biotechnology
Gelonghui, May 8, 丨 Nanhua Biology (000504.SZ) said on the investor interactive platform that the company does not yet have synthetic biotechnology-related technology. The company's biomedical business is mainly cell storage, and also studies applications and services related to stem cells and immune cells. Among them, cell storage includes stem cell storage and immune cell storage. Applied research mainly includes stem cells to treat lung damage, mesenchymal stem cells treat gestational diabetes, basic and clinical research on stem cells to treat kidney disease, research on the molecular mechanisms of umbilical cord mesenchymal stem cell exosomes in skin damage repair, and umbilical cord mesenchymal stem cells
Nanhua Biotech (000504.SZ): Net loss of 2.777 million yuan in the first quarter
Gelonghui, April 29丨Nanhua Biotech (000504.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 25.973,900 yuan, down 25.23% from the previous year; net profit attributable to shareholders of listed companies was 2.777 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 3.834 million yuan; basic earnings per share.
Express News | Nanhua Biotech: All 10.79% of the company's shares held by Shanghai Heping, the second-largest shareholder will be judicially auctioned
Nanhua Biotech (000504.SZ): Pre-loss of 19 million yuan to 28 million yuan in 2023
Gelonghui, January 26 | Nanhua Biotech (000504.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 19 million yuan to 28 million yuan, down 49.67 percent- 120.56% from the same period last year; net profit loss after deducting non-recurring profit and loss was 33.5 million yuan — 42.5 million yuan, down 45.33% -84.38% from the same period last year; basic earnings loss per share was 0.058 yuan/share — 0.085 yuan/share. Reasons for changes in performance: 1. During the reporting period, company cells
The court froze 10.79% of the shares held by Shanghai Heping, the majority shareholder of Nanhua Biotech (000504.SZ)
Nanhua Biotech (000504.SZ) issued an announcement. The company recently received an issuance from China Securities Registration and Settlement Co., Ltd...
Nanhua Biotech (000504.SZ): Net profit for the third quarter was 9.4599 million yuan, up 681.72% year on year
On October 30, Gelonghui Biotech (000504.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 34.3262 million yuan, down 26.38% year on year; net profit attributable to shareholders of listed companies was 9.4599 million yuan, up 681.72% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 463443 million yuan; basic earnings per share of 0.0304 yuan.
Nanhua Biotech (000504.SZ): At present, it has developed the EE18 series of products, mainly essences, masks, creams, etc.
GLONGHUI September 18丨An investor asked Nanhua Biotech (000504.SZ) on the investor interactive platform, “How are the company's medical and aesthetic products progressing?” The company replied that the company has now developed the EE18 series of products, mainly essences, masks, creams, etc. In addition, the company also has some products under development.
Nanhua Biotech (000504.SZ): The reserve price for listing and transferring 2 of its own properties located in Haikou City, Hainan Province is 209.76 million yuan
On August 7, GLONGHUA BIOLOGICAL (000504.SZ) announced that in order to revitalize idle assets, optimize asset structure, and improve asset operation efficiency, Nanhua Biomedical Co., Ltd. plans to transfer 2 owned properties located in Haikou City, Hainan Province through public listing to Hunan Joint Property Exchange Co., Ltd. The company's current real estate transfer price will be based on the evaluation report issued by Shenzhen Pengxin Asset Assessment Land and Real Estate Appraisal Co., Ltd. (Pengxin Capital Assessment [2023] No. 187), and finally determined that the listing reserve price for the two owned properties was 209.776 million yuan.
Nanhua Biotech (000504.SZ)'s application to issue shares to a specific target was approved by the Shenzhen Stock Exchange
According to the Zhitong Finance App, Nanhua Biotech (000504.SZ) issued an announcement. On July 12, 2023, the company received the “Notice of Opinions from the Review Center on Nanhua Biomedical Co., Ltd.'s Application for Issuance of Shares to Specific Targets” issued by the Shenzhen Stock Exchange Listing Review Center. The issuance and listing review agency of the Shenzhen Stock Exchange reviewed the company's application documents for the issuance of shares to specific targets and found that the company met the issuance conditions, listing conditions, and information disclosure requirements. In the future, the Shenzhen Stock Exchange will report it to the China Securities Regulatory Commission to complete the relevant registration procedures in accordance with the regulations.
Express News | The Nanhua Biotech Annual Report was questioned: The request explains the main reason why Hongyuan Thermal Power is both the company's supplier and customer, and whether the relevant orders were bought and sold by oneself
Nanhua Biotech (000504.SZ) announced first-quarter results, with a net loss of 1,976 million yuan, moving from profit to loss
According to the Zhitong Finance App, Nanhua Biotech (000504.SZ) disclosed its report for the first quarter of 2023. The company's operating income was 347396 million yuan, a decrease of 46.40% over the previous year; net loss attributable to shareholders of listed companies was 1,976 million yuan, moving from profit to loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.4914 million yuan, an increase in loss over the previous year; a basic loss of 0.0063 yuan per share.
Nanhua Biotech (000504.SZ): Fixed increase application accepted by Shenzhen Stock Exchange
Gelonghui, April 27丨Nanhua Biotech (000504.SZ) announced that the company recently received the “Notice Concerning Acceptance of Application Documents for Nanhua Biomedical Co., Ltd. to Issuance of Shares to Specific Targets” issued by the Shenzhen Stock Exchange (“Shenzhen Stock Exchange”) (Shenzhen Stock Exchange [2023] No. 348). The Shenzhen Stock Exchange checked the application documents submitted by the company to issue shares to specific targets, believing that the application documents were complete and decided to accept them.
Nanhua Biotech (000504.SZ): 2022 net loss of 126.948 million yuan
Gelonghui, April 20, 丨 Nanhua Biotech (000504.SZ) announced its 2022 annual report. The company achieved operating income of 200 million yuan in 2022, an increase of 27.92% over the previous year; net profit attributable to shareholders of listed companies was -126.948 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -23.05 million yuan; basic earnings per share were -0.04 yuan.
Nanhua Biotech (000504.SZ) made a forecast loss, with a net loss of 9.5 million yuan to 14 million yuan in 2022
According to the Zhitong Finance App, Nanhua Biotech (000504.SZ) released its 2022 annual results forecast, with a net loss of 9.5 million yuan to 14 million yuan attributable to shareholders of listed companies. However, a loss of 19.126,000 yuan was achieved in the same period last year. Net loss after deducting non-recurring profit and loss was $21 million — $25.5 million. During the reporting period, the company's total revenue increased compared to the previous year, but due to factors such as the unstable market environment and rising operating costs, the company's overall revenue failed to cover the overall costs. The relevant instructions are as follows: 1. Affected by the epidemic, the company's stem cell business operates in some areas where the company operates
Nanhua Biotech (000504.SZ) received 90413 million yuan of interest exemption from indirect controlling shareholders
According to the Zhitong Finance App, Nanhua Biotech (000504.SZ) issued an announcement that the company accepted Hunan Caixin Financial Holding Group Co., Ltd. (“Caixin Financial Holdings”), the indirect controlling shareholder of the company, to exempt the company from interest payable by the company of 9.043 million yuan. This related transaction occurred by Caixin Financial Holdings to support the company's continued steady development. It will help the company relieve debt pressure and improve the company's financial situation.
Nanhua Biotech (000504.SZ) and its subsidiaries have received a total of 5.275,000 yuan in government subsidies since the beginning of the year
Gelonghui, November 10, 丨 Nanhua Biotech (000504.SZ) announced that from January 1, 2022 to the date of this announcement, the company and its subsidiaries Aisplin, Boai Kangmin, Aisweimin, and Chengguang Energy received a total of 5.275 million yuan in government grants.
Nanhua Biotech (000504.SZ) plans to acquire 29% of Aisplin's shares for no more than 9.715 million yuan
According to the Zhitong Finance App, Nanhua Biotech (000504.SZ) issued an announcement. The company held the 9th meeting of the 11th board of directors on October 28, 2022. The meeting deliberated and passed the “Proposal on the Proposed Acquisition of Minority Shareholders' Rights of Holding Subsidiaries”. In order to strengthen the ability to lay out the stem cell business, the company plans to use its own capital or self-funded capital to acquire 12.25% (corresponding investment amount of 735,000 yuan), 15.00% (corresponding investment amount of 900,000 yuan), 1.75% (corresponding investment amount of 900,000 yuan), 1.75% (corresponding investment amount of 900,000 yuan) Hunan (105,000 yuan)
Analysis
Price Target
No Data
